BioMeetingpoint at the Biotechnica

The Biotechnology Thematic Group (BioTG) of the IRC Network together with other European partners are organising again the BioMeetingpoint for companies, R&D organisations and stakeholders to hold bilateral meetings at Biotechnica Hannover, Europe's leading biotechnology trade fair, which will take place in Hannover, Germany 9 - 11 October 2007.

Since 1985 Biotechnica Hannover has been the most important trade show in Europe for biotechnology. For the BioMeetingpoint a catalogue of company profiles and technology offers and requests will be available electronically and will allow participating companies and organisations to organise their individual meetings in advance.

The BioMeetingpoint functions as an "interface between research and the private sector" allowing new technologies, processes, patents and licenses to be offered and experience in financing, production, marketing and distribution to be requested, thus bringing compatible partners together.

The BioMeetingpoint is the ideal environment for:

  • Enterprises offering and/or using innovative technologies.
  • Enterprises that are looking for expertise and know-how in the areas of production, marketing and distribution or wish to provide this knowledge to others.
  • Scientists and research institutes offering application-oriented research results.
  • Start-ups.
  • Investors.

They will have the opportunity to get to know selected partners during individual discussions, which aim to pave the way for future co-operations.

For further information, please visit:
http://www.biomeetingpoint.org

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Soy lecithin NSAID combo drug protects against can…

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSA...

Novartis receives positive CHMP opinion for Aimovi…

Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Aimovig® (erenumab) for t...

FDA takes action against 53 websites marketing una…

The U.S. Food and Drug Administration today announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing p...